CA2915413C - Formulation contenant un rapport fixe insuline glargine/lixisenatide - Google Patents

Formulation contenant un rapport fixe insuline glargine/lixisenatide

Info

Publication number
CA2915413C
CA2915413C CA2915413A CA2915413A CA2915413C CA 2915413 C CA2915413 C CA 2915413C CA 2915413 A CA2915413 A CA 2915413A CA 2915413 A CA2915413 A CA 2915413A CA 2915413 C CA2915413 C CA 2915413C
Authority
CA
Canada
Prior art keywords
insulin glargine
compound
composition
mmol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2915413A
Other languages
English (en)
Other versions
CA2915413A1 (fr
Inventor
Elisabeth SOUHAMI
Louise SILVESTRE
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority claimed from PCT/EP2014/062418 external-priority patent/WO2014202483A1/fr
Publication of CA2915413A1 publication Critical patent/CA2915413A1/fr
Application granted granted Critical
Publication of CA2915413C publication Critical patent/CA2915413C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une composition pharmaceutique comprenant a) du lixisénatide ou/et un sel pharmaceutiquement acceptable de celui-ci, et (b) de l'insuline glargine ou/et un sel pharmaceutiquement acceptable de celle-ci, le composé (b) et le composé (a) étant présents selon un rapport fixe.
CA2915413A 2013-06-17 2014-06-13 Formulation contenant un rapport fixe insuline glargine/lixisenatide Active CA2915413C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13172341.3 2013-06-17
EP13172341 2013-06-17
EP13192556 2013-11-12
EP13192556.2 2013-11-12
PCT/EP2014/062418 WO2014202483A1 (fr) 2013-06-17 2014-06-13 Formulation contenant un rapport fixe insuline glargine/lixisénatide

Publications (2)

Publication Number Publication Date
CA2915413A1 CA2915413A1 (fr) 2014-12-24
CA2915413C true CA2915413C (fr) 2025-07-22

Family

ID=

Similar Documents

Publication Publication Date Title
US20250064898A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
US20250134964A1 (en) Method for inducing weight loss in a type 2 diabetes mellitus patient
US20220054594A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
AU2012328388B2 (en) Treatment protocol of diabetes type 2
CA2915413C (fr) Formulation contenant un rapport fixe insuline glargine/lixisenatide
HK1217429B (en) Insulin glargine/lixisenatide fixed ratio formulation
NZ715144B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
CA2685636C (fr) Methode destinee au traitement du diabete de type 2 comprenant un traitement d'appoint par la metformine
HK1194307B (en) Lixisenatide and metformin for treatment of diabetes type 2
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2